Growing Revenue Streams Chroma's recent financial performance demonstrates significant revenue growth driven by its flagship product Niagen and NAD+ precursors, with a 37% increase in revenue and elevated gross margins, indicating a strong market demand and opportunity to expand sales efforts within health and wellness sectors.

Industry Positioning As the global authority on NAD+ science with a focus on healthy aging, Chroma presents an attractive opportunity to partner with companies in biotech, supplements, and longevity markets seeking innovative solutions aligned with current health trend movements.

Recent Corporate Rebranding The company's transition to Niagen Bioscience and its visibility at industry conferences positions it well to attract new clients interested in NAD+ research, aging science, and related health products, offering potential collaborative or distribution opportunities.

Market Trends Leveraged Chroma's capitalizing on the longevity and healthy aging boom provides a strategic opening to target consumer brands, health tech firms, and supplement manufacturers looking to incorporate NAD+ technologies or partner for co-developments in this expanding market segment.

Technology & Innovation With a focus on science-backed NAD+ solutions and a track record of product innovation, Chroma offers a compelling value proposition for collaboration with R&D-focused organizations, biotech investors, and brands seeking cutting-edge health science integrations.